Special Issue "The Role of Natural Products on Diabetes Mellitus Treatment, 2nd Edition"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1235

Special Issue Editors

Departamento de Farmácia, Facultad de Ciencias, Universidad Nacional de Colombia, Cra. 30 45-03, Bogotá 111321, DC, Colombia
Interests: drug delivery systems; pharmacokinetics; bioavailability; microparticles; nanoparticles; self-emulsifying delivery systems; extracts standardization
Special Issues, Collections and Topics in MDPI journals
Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil
Interests: endocrine physiology; male reproduction; diabetes; hormone action mechanism; natural products and analogues; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia due to the secretion and/or action of insulin. This disease of high incidence and prevalence affects the quality of life and productivity of the population that suffers from it. Although there are drugs that have been widely used in the treatment of this disease, at present the search for possible antidiabetic agents continues, especially for those that have more than one mechanism of action, taking into account the complexity of this pathology.

Metformin (a biguanide), which is a derivative of galegin, is among the first-line therapies for the treatment of type II DM. This guanidine was isolated from Galega officinalis L., a plant that has been used since the Middle Ages by diabetic patients. This fact has aroused interest in the use of medicinal plants and their secondary metabolites as possible drugs in DM treatment. Although it is difficult to find a substitute for insulin among plants, it is possible that molecules can be found that stimulate endogenous insulin biosynthesis and secretion or increase glucose absorption in blood by peripheral tissues, by acting as insulinomimetic or insulin secretagogic agents.

Following on from the above, this second edition of the Special Issue is focused on the study of natural products (characterized extracts and isolated secondary metabolites) in the treatment of diabetes mellitus complications by in vivo and in vitro assays. Clinical trials are also welcome.

Prof. Dr. Diana Marcela Aragon Novoa
Prof. Dr. Fátima Regina Mena Barreto Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • diabetes mellitus
  • natural products
  • secondary metabolites
  • insulin secretagogue
  • oxidative stress
  • insulin response
  • blood glucose levels
  • hyperglycemia
  • insulinomimetic

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Systematic Review
Comparative Efficacy of East Asian Herbal Formulae Containing Astragali Radix–Cinnamomi Ramulus Herb-Pair against Diabetic Peripheral Neuropathy and Mechanism Prediction: A Bayesian Network Meta-Analysis Integrated with Network Pharmacology
Pharmaceutics 2023, 15(5), 1361; https://doi.org/10.3390/pharmaceutics15051361 - 28 Apr 2023
Cited by 2 | Viewed by 982
The Astragali Radix–Cinnamomi Ramulus herb-pair (ACP) has been widely used in the treatment of diabetic peripheral neuropathy (DPN) as part of East Asian herbal medicine (EAHM). Eligible randomized controlled trials (RCTs) were identified by searching 10 databases. The outcomes investigated were response rate, [...] Read more.
The Astragali Radix–Cinnamomi Ramulus herb-pair (ACP) has been widely used in the treatment of diabetic peripheral neuropathy (DPN) as part of East Asian herbal medicine (EAHM). Eligible randomized controlled trials (RCTs) were identified by searching 10 databases. The outcomes investigated were response rate, sensory nerve conduction velocity (SNCV), and motor nerve conduction velocity (MNCV) in four regions of the body. The compounds in the ACP and their targets of action, disease targets, common targets, and other relevant information were filtered using network pharmacology. Forty-eight RCTs, with 4308 participants, and 16 different interventions were identified. Significant differences were observed in the response rate, MNCV, and SNCV, as all EAHM interventions were superior to conventional medicine or lifestyle modification. The EAHM formula containing the ACP ranked highest in more than half of the assessed outcomes. Furthermore, major compounds, such as quercetin, kaempferol, isorhamnetin, formononetin, and beta-sitosterol, were found to suppress the symptoms of DPN. The results of this study suggest that EAHM may increase therapeutic efficacy in DPN management, and EAHM formulations containing the ACP may be more suitable for improving treatment response rates to NCV and DPN therapy. Full article
Show Figures

Graphical abstract

Back to TopTop